Literature DB >> 23721966

Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia.

André Zugman1, Ary Gadelha, Idaiane Assunção, João Sato, Vanessa K Ota, Deyvis L Rocha, Jair J Mari, Sintia I Belangero, Rodrigo A Bressan, Elisa Brietzke, Andrea P Jackowski.   

Abstract

BACKGROUND: Treatment resistance affects up to one third of patients with schizophrenia (SCZ). A better understanding of its biological underlying processes could improve treatment. The aim of this study was to compare cortical thickness between non-resistant SCZ (NR-SCZ), treatment-resistant SCZ (TR-SCZ) patients and healthy controls (HC).
METHODOLOGY: Structural MRI scans were obtained from 3 groups of individuals: 61 treatment resistant SCZ individuals, 67 non-resistant SCZ and 80 healthy controls. Images were analyzed using cortical surface modelling (implemented in freesurfer package) to identify group differences in cortical thickness. Statistical significant differences were identified using Monte-Carlo simulation method with a corrected p-cluster<0.01.
RESULTS: Patients in the TR-SCZ group showed a widespread reduction in cortical thickness in frontal, parietal, temporal and occipital regions bilaterally. NR-SCZ group had reduced cortex in two regions (left superior frontal cortex and left caudal middle frontal cortex). TR-SCZ group also showed decreased thickness in the left dorsolateral prefrontal cortex (DLPFC) when compared with patients from NR-SCZ group.
CONCLUSIONS: The reduction in cortical thickness in DLPFC indicates a more severe form of the disease or a specific finding for this group. Alterations in this region should be explored as a putative marker for treatment resistance. Prospective studies, with individuals being followed from first episode psychosis until refractoriness is diagnosed, are needed to clarify these hypotheses.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cortical thickness; MRI; Refractory; Schizophrenia; Treatment resistant

Mesh:

Substances:

Year:  2013        PMID: 23721966     DOI: 10.1016/j.schres.2013.05.002

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  17 in total

Review 1.  Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies.

Authors:  Goda Tarcijonas; Deepak K Sarpal
Journal:  Neurobiol Dis       Date:  2018-06-25       Impact factor: 5.996

Review 2.  Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

Authors:  Shinichiro Nakajima; Hiroyoshi Takeuchi; Eric Plitman; Gagan Fervaha; Philip Gerretsen; Fernando Caravaggio; Jun Ku Chung; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Res       Date:  2015-02-13       Impact factor: 4.939

Review 3.  Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.

Authors:  Masataka Wada; Yoshihiro Noda; Yusuke Iwata; Sakiko Tsugawa; Kazunari Yoshida; Hideaki Tani; Yoji Hirano; Shinsuke Koike; Daiki Sasabayashi; Haruyuki Katayama; Eric Plitman; Kazutaka Ohi; Fumihiko Ueno; Fernando Caravaggio; Teruki Koizumi; Philip Gerretsen; Takefumi Suzuki; Hiroyuki Uchida; Daniel J Müller; Masaru Mimura; Gary Remington; Anthony A Grace; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2022-04-20       Impact factor: 15.992

4.  Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment.

Authors:  Giulia Tronchin; Theophilus N Akudjedu; Mohamed Ahmed; Laurena Holleran; Brian Hallahan; Dara M Cannon; Colm McDonald
Journal:  Neuropsychopharmacology       Date:  2020-04-08       Impact factor: 7.853

5.  Systems-Level Analysis of Genetic Variants Reveals Functional and Spatiotemporal Context in Treatment-resistant Schizophrenia.

Authors:  Fernanda Talarico; Giovany Oliveira Costa; Vanessa Kiyomi Ota; Marcos Leite Santoro; Cristiano Noto; Ary Gadelha; Rodrigo Bressan; Hatylas Azevedo; Sintia Iole Belangero
Journal:  Mol Neurobiol       Date:  2022-03-12       Impact factor: 5.590

6.  Extensive gray matter volume reduction in treatment-resistant schizophrenia.

Authors:  Valerie M Anderson; Meghan E Goldstein; Robert R Kydd; Bruce R Russell
Journal:  Int J Neuropsychopharmacol       Date:  2015-02-25       Impact factor: 5.176

Review 7.  Multidimensional Connectomics and Treatment-Resistant Schizophrenia: Linking Phenotypic Circuits to Targeted Therapeutics.

Authors:  Mary-Anne B MacKay; John W Paylor; James T F Wong; Ian R Winship; Glen B Baker; Serdar M Dursun
Journal:  Front Psychiatry       Date:  2018-10-30       Impact factor: 4.157

Review 8.  Brain-imaging studies of treatment-resistant schizophrenia: a systematic review.

Authors:  Elias Mouchlianitis; Robert McCutcheon; Oliver D Howes
Journal:  Lancet Psychiatry       Date:  2016-03-04       Impact factor: 27.083

9.  Antipsychotics Effects on Network-Level Reconfiguration of Cortical Morphometry in First-Episode Schizophrenia.

Authors:  Yuchao Jiang; Yingchan Wang; Huan Huang; Hui He; Yingying Tang; Wenjun Su; Lihua Xu; Yanyan Wei; Tianhong Zhang; Hao Hu; Jinhong Wang; Dezhong Yao; Jijun Wang; Cheng Luo
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 7.348

10.  PRODH polymorphisms, cortical volumes and thickness in schizophrenia.

Authors:  Vanessa K Ota; Fernanda T Bellucco; Ary Gadelha; Marcos L Santoro; Cristiano Noto; Denise M Christofolini; Idaiane B Assunção; Karen M Yamada; Andrea K Ribeiro-dos-Santos; Sidney Santos; Jair J Mari; Marília A C Smith; Maria I Melaragno; Rodrigo A Bressan; João R Sato; Andrea P Jackowski; Sintia I Belangero
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.